Royal Bank of Canada
CRSP icon

Royal Bank of Canada’s CRISPR Therapeutics CRSP Stock Holding History

Royal Bank of Canada’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.79M Sell
163,720
-1,845
-1% -$97.3K ﹤0.01% 2093
2025
Q4 		$8.68M Sell
165,565
-300,605
-64% -$18M ﹤0.01% 2038
2025
Q3 		$30.2M Buy
466,170
+129,032
+38% +$7.41M 0.01% 1314
2025
Q2 		$16.4M Buy
337,138
+194,442
+136% +$7.52M ﹤0.01% 1677
2025
Q1 		$4.86M Buy
142,696
+31,392
+28% +$1.33M ﹤0.01% 2281
2024
Q4 		$4.38M Sell
111,304
-8,867
-7% -$419K ﹤0.01% 2425
2024
Q3 		$5.65M Buy
120,171
+33,768
+39% +$1.71M ﹤0.01% 2183
2024
Q2 		$4.67M Buy
86,403
+1,628
+2% +$94.2K ﹤0.01% 2243
2024
Q1 		$5.78M Sell
84,775
-5,608
-6% -$401K ﹤0.01% 2064
2023
Q4 		$5.66M Sell
90,383
-6,552
-7% -$362K ﹤0.01% 2149
2023
Q3 		$4.4M Sell
96,935
-2,098
-2% -$108K ﹤0.01% 2192
2023
Q2 		$5.56M Buy
99,033
+2,791
+3% +$158K ﹤0.01% 2025
2023
Q1 		$4.35M Sell
96,242
-3,364
-3% -$163K ﹤0.01% 2184
2022
Q4 		$4.05M Sell
99,606
-34,765
-26% -$1.84M ﹤0.01% 2301
2022
Q3 		$8.78M Sell
134,371
-91,146
-40% -$6.61M ﹤0.01% 1638
2022
Q2 		$13.7M Sell
225,517
-16,466
-7% -$968K ﹤0.01% 1353
2022
Q1 		$15.2M Buy
241,983
+3,651
+2% +$229K ﹤0.01% 1426
2021
Q4 		$18.1M Sell
238,332
-1,511
-0.6% -$132K ﹤0.01% 1457
2021
Q3 		$26.8M Buy
239,843
+3,883
+2% +$488K 0.01% 1132
2021
Q2 		$38.2M Buy
235,960
+6,372
+3% +$775K 0.01% 900
2021
Q1 		$28M Buy
229,588
+7,475
+3% +$1.13M 0.01% 1064
2020
Q4 		$34M Buy
222,113
+19,441
+10% +$2.3M 0.01% 906
2020
Q3 		$17M Buy
202,672
+23,730
+13% +$2.1M 0.01% 1193
2020
Q2 		$13.2M Buy
178,942
+64,285
+56% +$3.76M 0.01% 1283
2020
Q1 		$4.86M Buy
114,657
+6,420
+6% +$331K ﹤0.01% 1822
2019
Q4 		$6.59M Buy
108,237
+2,206
+2% +$120K ﹤0.01% 1946
2019
Q3 		$4.35M Sell
106,031
-14,394
-12% -$688K ﹤0.01% 2191
2019
Q2 		$5.67M Buy
120,425
+51,665
+75% +$2.06M ﹤0.01% 1976
2019
Q1 		$2.46M Buy
68,760
+8,973
+15% +$310K ﹤0.01% 2534
2018
Q4 		$1.71M Sell
59,787
-16,971
-22% -$590K ﹤0.01% 2762
2018
Q3 		$3.4M Buy
76,758
+22,866
+42% +$1.2M ﹤0.01% 2435
2018
Q2 		$3.17M Buy
53,892
+27,272
+102% +$1.55M ﹤0.01% 2368
2018
Q1 		$1.22M Buy
26,620
+12,751
+92% +$526K ﹤0.01% 3027
2017
Q4 		$325K Buy
13,869
+6,019
+77% +$114K ﹤0.01% 4115
2017
Q3 		$140K Buy
7,850
+4,525
+136% +$82K ﹤0.01% 4776
2017
Q2 		$53K Sell
3,325
-51
-2% -$842 ﹤0.01% 5086
2017
Q1 		$74K Buy
+3,376
New +$66.3K ﹤0.01% 4924

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royal Bank of Canada's CRSP Position: Q1 2026 in Review

Royal Bank of Canada reduced its CRISPR Therapeutics (CRSP) stake by 1.1% in Q1 2026, selling an estimated $97.3K and leaving 163,720 shares worth $7.79M. The position accounts for ﹤0.01% of the portfolio, ranked #2093.

Royal Bank of Canada first reported a position in CRSP in Q1 2017 and has held it in 37 quarters since. The position peaked at $38.2M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Royal Bank of Canada held 163,720 shares of CRISPR Therapeutics worth $7.79M as of Q1 2026.
  • Royal Bank of Canada sold 1,845 CRISPR Therapeutics shares in Q1 2026, an estimated $97.3K.
  • CRISPR Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #2093 holding.
  • Royal Bank of Canada first reported a position in CRISPR Therapeutics in Q1 2017 and has held it in 37 quarters since.
  • Royal Bank of Canada's CRISPR Therapeutics position peaked at $38.2M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.